NCT06925685Enrolling by invitation
Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell Product
Long Term Follow up Study for Participants Treated With an Allogeneic CAR T-Cell Product in a Prior Clinical Study
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 7 Apr 2025
- Start date
- 31 Jan 2025
- Primary completion date
- 31 Jan 2039
- Lead sponsor
- Allogene Therapeutics
- Diseases
- Childhood cancers
- NCT number
- NCT06925685
What you commit to
- Study type: Observational
- Planned participants: 50
- From 31 Jan 2025 to the primary completion date, 31 Jan 2039
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor
Who the study is looking for
- Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Circuit Clinical Coordinator of this site? Confirm its status | Buffalo | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.